InVasc’s INV-144 is a combination drug of losartan and alpha Lipoic Acid (ALA), which is used to slow down the progression of chronic kidney disease (CKD) in patients with hypertensive diabetic patients.
Earlier, INV-144’s sister compound INV-141 showed positive results and demonstrated reduction reduction of proteinuria in the same patient population.
InVasc CEO William Johnston said the study allows them to compare INV-144 to an early version of the drug, INV-141, that previously demonstrated statistical significance in similar patients.
"We anticipate that this study will provide the data needed to move forward with additional studies designed to optimize this combination drug," Johnston said.